This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Dexamethasone metasulfobenzoate is an ophthalmic and auricular corticosteroid used with antibiotics for the treatment of otitis externa, blepharitis, and other inflammatory eye conditions.

Brand Names
Sofracort
Generic Name
Dexamethasone metasulfobenzoate
DrugBank Accession Number
DB14703
Background

Not Available

Type
Small Molecule
Groups
Approved, Experimental
Structure
Weight
Average: 576.63
Monoisotopic: 576.18293198
Chemical Formula
C29H33FO9S
Synonyms
  • Dexamethasone m-sulfobenzoate
  • Dexamethasone-21-sulfobenzoate

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Dexamethasone sodium metasulfobenzoate4T1RAI19H83936-02-5RPBJOYICBFNIMN-RDWMNNCQSA-M
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
POLYDEXA EAR DROPSDexamethasone sodium metasulfobenzoate (0.1 g/100ml) + Neomycin sulfate (650000 iu/100ml) + Polymyxin B sulfate (1000000 iu/100ml)SolutionAuricular (otic)PHARMACON PTE LTD1990-07-16Not applicable
Sandoz OpticortDexamethasone sodium metasulfobenzoate (0.5 mg / mL) + Framycetin sulfate (5 mg / mL) + Gramicidin D (0.05 mg / mL)SolutionAuricular (otic); OphthalmicSandoz Canada Incorporated2004-01-162019-08-01Canada flag
SofracortDexamethasone sodium metasulfobenzoate (0.5 mg / mL) + Framycetin sulfate (5 mg / mL) + Gramicidin D (0.05 mg / mL)Solution / dropsAuricular (otic); OphthalmicSanofi Aventis2002-07-26Not applicableCanada flag
Sofracort Eye/ear DropsDexamethasone sodium metasulfobenzoate (0.5 mg / mL) + Framycetin sulfate (5 mg / mL) + Gramicidin D (0.05 mg / mL)Solution / dropsAuricular (otic); OphthalmicRoussel Canada Inc.1966-12-311996-09-09Canada flag
Sofracort Sterile Ear/eye DropsDexamethasone sodium metasulfobenzoate (0.5 mg / mL) + Framycetin sulfate (5 mg / mL) + Gramicidin D (0.05 mg / mL)Solution / dropsTopicalHoechst Roussel Canada Inc.1966-12-312004-07-30Canada flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
C67221CB9Q
CAS number
16978-57-7
InChI Key
TWQWRHIQRAZHPR-XNXCGYEVSA-N
InChI
InChI=1S/C29H33FO9S/c1-16-11-22-21-8-7-18-13-19(31)9-10-26(18,2)28(21,30)23(32)14-27(22,3)29(16,35)24(33)15-39-25(34)17-5-4-6-20(12-17)40(36,37)38/h4-6,9-10,12-13,16,21-23,32,35H,7-8,11,14-15H2,1-3H3,(H,36,37,38)/t16-,21+,22+,23+,26+,27+,28+,29+/m1/s1
IUPAC Name
3-({2-[(1R,2R,3aS,3bS,9aS,9bR,10S,11aS)-9b-fluoro-1,10-dihydroxy-2,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}carbonyl)benzene-1-sulfonic acid
SMILES
[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)C3=CC=CC(=C3)S(O)(=O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

References

General References
Not Available
ChemSpider
56740
ChEMBL
CHEMBL3305965
ZINC
ZINC000004212887

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Unknown StatusTreatmentAnesthesia Complications / Hemodynamics Instability / Nausea / Paralytic Ileus / Postoperative pain / Vomiting1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionAuricular (otic)0.1 g/100ml
SolutionAuricular (otic); Ophthalmic
Solution / dropsAuricular (otic); Ophthalmic
Solution / dropsTopical
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0457 mg/mLALOGPS
logP1.87ALOGPS
logP1.22ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)-2.5ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area155.27 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity142.94 m3·mol-1ChemAxon
Polarizability57.93 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at September 21, 2018 14:26 / Updated at June 12, 2020 16:53